Literature DB >> 1677300

Alpha 2-adrenoceptor blocking profile of SK&F 104078: further evidence for receptor subtypes.

I Akers1, J Coates, G M Drew, A T Sullivan.   

Abstract

1. The ability of the putative, selective post-junctional alpha 2-adrenoceptor antagonist, SK&F 104078 to antagonize the effects of structurally-diverse agonists at pre-junctional alpha 2-adrenoceptors in the guinea-pig ileum and rat vas deferens in vitro and in the rat heart in vivo, and at post-junctional alpha 2-adrenoceptors in the rabbit ear vein in vitro, was examined. Results obtained with SK&F 104078 were compared with those obtained with yohimbine. 2. Xylazine and B-HT933 each caused a concentration-dependent inhibition of the field-stimulation-evoked twitch responses of the guinea-pig ileum and rat vas deferens. SK&F 104078 did not antagonize either agonist in the guinea-pig ileum and exerted only minimal blocking activity against xylazine in the rat vas deferens. In contrast, SK&F 104078 competitively antagonized B-HT933 in the rat vas deferens (pA2 = 6.45). Yohimbine competitively antagonized both agonists in each tissue (pA2 values ranged between 7.46 and 7.88). 3. In the pithed rat xylazine and B-HT933, injected intravenously, caused a dose-dependent reduction in the tachycardia elicited by stimulation of the cardiac preganglionic sympathetic nerves. SK&F 104078 (10 mg kg-1, i.v.) caused a 20-30 fold rightward displacement of the dose-response curve to xylazine, but did not affect responses to B-HT933. Yohimbine (1 mg kg-1, i.v.) antagonized both agonists to a similar degree. 4. In the rabbit ear vein xylazine, B-HT933, noradrenaline and UK 14304 elicted vasoconstrictor responses. Prazosin was without effect, but in contrast, SK&F 104078 was a competitive antagonist of each of the agonists (pA2 values ranged between 6.63 and 6.72). Yohimbine also competitively antagonized each of the agonists in this preparation (pA2 values ranged between 7.81 and 8.07). 5. SK&F 104078 was also a competitive antagonist (pA2 = 6.20) against noradrenaline at post-junctional alpha 1-adrenoceptors in the rabbit aorta. 6. These data show that SK&F 104078 is a competitive antagonist at post-junctional alpha l- and alpha 2-adrenoceptors. Its antagonist potency at pre-junctional alpha 2-adrenoceptors is agonist- and tissuedependent. Yohimbine does not discriminate between pre- and post-junctional alpha 2-adrenoceptors. The findings are discussed in terms of the possible existence of subclasses of OC2-adrenoceptors.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1677300      PMCID: PMC1917985          DOI: 10.1111/j.1476-5381.1991.tb12281.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  18 in total

1.  Evidence that the population of postjunctional-adrenoceptors mediating contraction of smooth muscle in the rabbit isolated ear vein is predominantly alpha 2.

Authors:  C J Daly; J C McGrath; V G Wilson
Journal:  Br J Pharmacol       Date:  1988-08       Impact factor: 8.739

2.  Effects of alpha-adrenoceptor agonists and antagonists on pre- and postsynaptically located alpha-adrenoceptors.

Authors:  G M Drew
Journal:  Eur J Pharmacol       Date:  1976-04       Impact factor: 4.432

3.  Pharmacologic characterization of SK&F 104078, a novel alpha-2 adrenoceptor antagonist which discriminates between pre- and postjunctional alpha-2 adrenoceptors.

Authors:  J P Hieble; A C Sulpizio; A J Nichols; R N Willette; R R Ruffolo
Journal:  J Pharmacol Exp Ther       Date:  1988-11       Impact factor: 4.030

4.  Evidence that SK & F 104078 does not differentiate between pre- and postjunctional alpha 2-adrenoceptors.

Authors:  S Connaughton; J R Docherty
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-10       Impact factor: 3.000

5.  What do antagonists tell us about alpha-adrenoceptors?

Authors:  G M Drew
Journal:  Clin Sci (Lond)       Date:  1985       Impact factor: 6.124

Review 6.  Subtypes of alpha 2-adrenoceptors: pharmacological and molecular biological evidence converge.

Authors:  D B Bylund
Journal:  Trends Pharmacol Sci       Date:  1988-10       Impact factor: 14.819

Review 7.  Heterogeneity of alpha-2 adrenergic receptors.

Authors:  D B Bylund
Journal:  Pharmacol Biochem Behav       Date:  1985-05       Impact factor: 3.533

8.  Cloning and expression of a human kidney cDNA for an alpha 2-adrenergic receptor subtype.

Authors:  J W Regan; T S Kobilka; T L Yang-Feng; M G Caron; R J Lefkowitz; B K Kobilka
Journal:  Proc Natl Acad Sci U S A       Date:  1988-09       Impact factor: 11.205

9.  Some quantitative uses of drug antagonists.

Authors:  O ARUNLAKSHANA; H O SCHILD
Journal:  Br J Pharmacol Chemother       Date:  1959-03

10.  Functional evidence for heterogeneity of peripheral prejunctional alpha 2-adrenoceptors.

Authors:  S Connaughton; J R Docherty
Journal:  Br J Pharmacol       Date:  1990-10       Impact factor: 8.739

View more
  3 in total

1.  Molecular and pharmacological identity of the alpha 2D-adrenergic receptor subtype in bovine retina and its photoreceptors.

Authors:  V Venkataraman; T Duda; K Galoian; R K Sharma
Journal:  Mol Cell Biochem       Date:  1996-06-21       Impact factor: 3.396

2.  Neurally evoked responses of human isolated resistance arteries are mediated by both alpha 1- and alpha 2-adrenoceptors.

Authors:  N A Parkinson; S M Thom; A D Hughes; P S Sever; M J Mulvany; H Nielsen
Journal:  Br J Pharmacol       Date:  1992-07       Impact factor: 8.739

3.  Subclassification of release-regulating alpha 2-autoreceptors in human brain cortex.

Authors:  M Raiteri; G Bonanno; G Maura; M Pende; G C Andrioli; A Ruelle
Journal:  Br J Pharmacol       Date:  1992-12       Impact factor: 8.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.